Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
RESEARCH FRONTIERS INC (REFR)
|
Add to portfolio |
|
|
|
| Price: |
$2.67
| | Metrics |
| OS: |
33.5
|
M
| |
|
|
| Market cap: |
$89.5
|
M
| |
|
|
|
Net cash:
|
$3.52
|
M
| |
$0.10
|
per share
|
|
EV:
|
$86
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($2.0)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.5 | 1.3 | 0.8 | 1.6 | 1.5 | 1.5 | 1.2 | 2.0 |
| Revenue growth | -57.3% | 52.5% | -47.0% | 5.1% | -1.4% | 22.1% | -38.4% | 25.6% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.5 | 1.3 | 0.8 | 1.6 | 1.5 | 1.5 | 1.2 | 2.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 3.2 | 3.1 | 3.4 | 4.7 | 3.9 | 3.9 | 5.5 | |
| Research and development | 0.6 | 0.6 | 0.6 | 1.0 | 0.9 | 0.8 | 1.4 | 1.6 |
| General and administrative | | | | | | | | 4.7 |
| EBIT | -2.6 | -1.8 | -2.6 | -3.2 | -2.4 | -2.4 | -4.3 | -4.3 |
| EBIT margin | -486.4% | -145.6% | -311.1% | -204.6% | -162.4% | -160.3% | -345.3% | -215.4% |
| Pre-tax income | -2.7 | -1.8 | -2.3 | -3.8 | -2.7 | -2.4 | -4.2 | -4.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -2.7 | -1.8 | -2.3 | -3.8 | -2.7 | -2.4 | -4.2 | -4.3 |
| Net margin | -494.6% | -146.2% | -282.6% | -243.5% | -180.4% | -160.0% | -342.9% | -213.2% |
| |
| Diluted EPS | ($0.08) | ($0.06) | ($0.07) | ($0.13) | ($0.10) | ($0.10) | ($0.18) | ($0.18) |
| Shares outstanding (diluted) | 32.1 | 31.6 | 31.5 | 30.0 | 26.0 | 24.0 | 24.0 | 24.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|